Moderator: Deborah Layton, PhD, FISPE – PEPI Consultancy Limited
### @@@ Christian Reich, MD – Observational Health Data Sciences and Informatics ### 1900387###Speaker###Principal Investigator###Observational Health Data Sciences and Informatics###Speaker: Christian Reich, MD – Observational Health Data Sciences and Informatics
### @@@ Morten Andersen, MD, PhD – Pharmacovigilance Research Center, Department of Drug Design and Pharmacology, University of Copenhagen ### 1302750###Speaker###Professor###Pharmacovigilance Research Center, Department of Drug Design and Pharmacology, University of Copenhagen###Speaker: Morten Andersen, MD, PhD – Pharmacovigilance Research Center, Department of Drug Design and Pharmacology, University of Copenhagen
### @@@ Daniel R. Morales, MBChB, BMSc, PhD, MRCP, MRCGP – European Medicines Agency ### 1062632###Speaker###Senior Clinical Epidemiologist###European Medicines Agency###Speaker: Daniel R. Morales, MBChB, BMSc, PhD, MRCP, MRCGP – European Medicines Agency
###Presenting Author: Julie Barberio (she/her/hers) – Department of Epidemiology, Emory University
### she/her/hers @@@ Rohini K. Hernandez, PhD MPH (she/her/hers) – Amgen, Inc. ### 1088313###Author###Director of Observational Research###Amgen, Inc.###Author: Rohini K. Hernandez, PhD MPH (she/her/hers) – Amgen, Inc.
### she/her/hers @@@ Ashley I. Naimi, PhD – Department of Epidemiology, Emory University ### 1655283###Author###Associate Professor###Department of Epidemiology, Emory University###Author: Ashley I. Naimi, PhD – Department of Epidemiology, Emory University
### @@@ Rachel E. Patzer, PhD – Department of Epidemiology, Emory University ### 1655284###Author###Professor###Department of Epidemiology, Emory University###Author: Rachel E. Patzer, PhD – Department of Epidemiology, Emory University
### @@@ Christopher Kim, PhD – Center for Observational Research, Amgen Inc. ### 1900271###Author###Director###Center for Observational Research, Amgen Inc.###Author: Christopher Kim, PhD – Center for Observational Research, Amgen Inc.
### @@@ Timothy L. Lash, DSc – Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA USA ### 1358745###Author###Professor and Chair###Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA USA###Author: Timothy L. Lash, DSc – Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA USA
### OP1-2Presenting Author: Junqing Xie, MBBS, MSc, DPhil – Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford
### @@@ Yaqing Gao, MPH – Oxford University ### 1900270###Author###Doctoral student###Oxford University###Author: Yaqing Gao, MPH – Oxford University
### @@@ Antonella Delmestri, PhD (she/her/hers) – Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford ### 1358614###Author###Lead Health Data Scientist###Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford###Author: Antonella Delmestri, PhD (she/her/hers) – Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford
### she/her/hers @@@ Sara Khalid, PhD – Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford ### 1358353###Author###Associate Professor###Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford###Author: Sara Khalid, PhD – Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford
### @@@ Gary S. Collins, PhD – Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford ### 1358613###Author###Professor###Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford###Author: Gary S. Collins, PhD – Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford
### @@@ Annika M. Jödicke, PhD (she/her/hers) – University of Oxford ### 1358980###Author###Senior Researcher in Pharmacoepidemiology###University of Oxford###Author: Annika M. Jödicke, PhD (she/her/hers) – University of Oxford
### she/her/hers @@@ Daniel Prieto-Alhambra, MD MSc(Oxon) PhD (he/him/his) – University of Oxford, Erasmus MC University ### 1062615###Author###Professor of Pharmaco- and Device Epidemiology, Professor of RWE###University of Oxford, Erasmus MC University###Author: Daniel Prieto-Alhambra, MD MSc(Oxon) PhD (he/him/his) – University of Oxford, Erasmus MC University
### he/him/his OP4-6Presenting Author: Yasmin Elsobky, B.Pharm.SCi, MS (she/her/hers) – ALNAS Hospital
### she/her/hers @@@ Diane L. Seger, RPh (she/her/hers) – Brigham and Women's Hospital ### 1359853###Author###Senior Pharmaco-Informatics Specialist###Brigham and Women's Hospital###Author: Diane L. Seger, RPh (she/her/hers) – Brigham and Women's Hospital
### she/her/hers @@@ David Bates, MD (he/him/his) – Brigham and Women's Hospital ### 1359858###Author###Chief, Division of General Internal Medicine and primary care###Brigham and Women's Hospital###Author: David Bates, MD (he/him/his) – Brigham and Women's Hospital
### he/him/his OP2-3Presenting Author: Sharon CM Essink, MSc (she/her/hers) – Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands. Department of Pharmacovigilance, Medicines Evaluation Board, Utrecht, The Netherlands.
### she/her/hers @@@ Inge M. Zomerdijk – Department of Pharmacovigilance, Medicines Evaluation Board, Utrecht, The Netherlands. ### 1659068###Author###Senior Pharmacovigilance assessor###Department of Pharmacovigilance, Medicines Evaluation Board, Utrecht, The Netherlands.###Author: Inge M. Zomerdijk – Department of Pharmacovigilance, Medicines Evaluation Board, Utrecht, The Netherlands.
### @@@ Sabine MJM Straus, MD, PhD – Department of Pharmacovigilance, Medicines Evaluation Board, Utrecht, The Netherlands. Department of Medical Informatics, Erasmus Medical Center, Rotterdam, The Netherlands. ### 1094834###Author###Chair of PRAC, associate professor###Department of Pharmacovigilance, Medicines Evaluation Board, Utrecht, The Netherlands. Department of Medical Informatics, Erasmus Medical Center, Rotterdam, The Netherlands.###Author: Sabine MJM Straus, MD, PhD – Department of Pharmacovigilance, Medicines Evaluation Board, Utrecht, The Netherlands. Department of Medical Informatics, Erasmus Medical Center, Rotterdam, The Netherlands.
### @@@ Helga Gardarsdottir, PharmD, PhD, – Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht University ### 1061395###Author###Associate professor###Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht University###Author: Helga Gardarsdottir, PharmD, PhD, – Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht University
### @@@ Marie Louise L. De Bruin, PhD (she/her/hers) – Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University ### 1360157###Author###Professor###Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University###Author: Marie Louise L. De Bruin, PhD (she/her/hers) – Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University
### she/her/hers OP4-3Presenting Author: Emeline Maisonneuve, MD (she/her/hers) – Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland
### she/her/hers @@@ Eva Gerbier – Pharmacy department, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland ### 1359620###Author###PhD student###Pharmacy department, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland###Author: Eva Gerbier – Pharmacy department, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
### @@@ Fatima Tauqeer – Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Research Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, , Oslo, Norway ### 1063106###Author###PhD student###Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Research Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, , Oslo, Norway###Author: Fatima Tauqeer – Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Research Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, , Oslo, Norway
### @@@ Léo Pomar, PhD – Materno-fetal and Obstetrics Research Unit, Woman-Mother-Child Department, CHUV, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland ### 1659156###Author###Midwife and Professor###Materno-fetal and Obstetrics Research Unit, Woman-Mother-Child Department, CHUV, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland###Author: Léo Pomar, PhD – Materno-fetal and Obstetrics Research Unit, Woman-Mother-Child Department, CHUV, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
### @@@ Guillaume Favre, MD – Materno-fetal and Obstetrics Research Unit, Woman-Mother-Child Department, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland ### 1659150###Author###PhD student###Materno-fetal and Obstetrics Research Unit, Woman-Mother-Child Department, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland###Author: Guillaume Favre, MD – Materno-fetal and Obstetrics Research Unit, Woman-Mother-Child Department, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
### @@@ Ursula Winterfeld, PhD – Pharmacy department, CHUV, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland ### 1359633###Author###Pharmacist###Pharmacy department, CHUV, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland###Author: Ursula Winterfeld, PhD – Pharmacy department, CHUV, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
### @@@ Anneke Passier, PhD – Teratology Information Service, Pharmacovigilance Centre Lareb, ‘s Hertogenbosch, The Netherlands ### 1900305###Author###Teratology information specialist###Teratology Information Service, Pharmacovigilance Centre Lareb, ‘s Hertogenbosch, The Netherlands###Author: Anneke Passier, PhD – Teratology Information Service, Pharmacovigilance Centre Lareb, ‘s Hertogenbosch, The Netherlands
### @@@ Alison Oliver, PhD – UKTIS, Newcastle upon Tyne Hospitals, NHS Foundation Trust and the UK Health Security Agency, Newcastle upon Tynes, UK ### 1900306###Author###Senior Medical Information Scientist###UKTIS, Newcastle upon Tyne Hospitals, NHS Foundation Trust and the UK Health Security Agency, Newcastle upon Tynes, UK###Author: Alison Oliver, PhD – UKTIS, Newcastle upon Tyne Hospitals, NHS Foundation Trust and the UK Health Security Agency, Newcastle upon Tynes, UK
### @@@ David Baud, MD PhD – Materno-fetal and Obstetrics Research Unit, Woman-Mother-Child department, CHUV Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland ### 1359631###Author###Head of department###Materno-fetal and Obstetrics Research Unit, Woman-Mother-Child department, CHUV Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland###Author: David Baud, MD PhD – Materno-fetal and Obstetrics Research Unit, Woman-Mother-Child department, CHUV Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
### @@@ Hedvig Nordeng, PhD – Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway ### 1358057###Author###Professor###Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway###Author: Hedvig Nordeng, PhD – Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway
### @@@ Michael Ceulemans, PhD – Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium ### 1900303###Author###Pharmacist and researcher###Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium###Author: Michael Ceulemans, PhD – Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium
### @@@ Alice Panchaud, PhD – Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland ### 1900290###Author###Head of BIHAM Pharmacy###Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland###Author: Alice Panchaud, PhD – Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland
### OP1-3Presenting Author: Kamika Reynolds, PhD – Sanofi
### @@@ Chintan Dave, PharmD, PhD – Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research, Rutgers University, New Brunswick, NJ ### 1655382###Author###Assistant Professor of Pharmacy and Epidemiology###Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research, Rutgers University, New Brunswick, NJ###Author: Chintan Dave, PharmD, PhD – Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research, Rutgers University, New Brunswick, NJ
### OP3-2Presenting Author: Anna-Belle Beau, PhD – Toulouse University Hospital, CERPOP-SPHERE Team, Inserm UMR 1295, Toulouse University, Toulouse, France
### @@@ Xavier Moisset – Université Clermont Auvergne, CHU de Clermont-Ferrand, Inserm, Neuro-Dol, Clermont-Ferrand ### 1900353###Author###Medical Doctor###Université Clermont Auvergne, CHU de Clermont-Ferrand, Inserm, Neuro-Dol, Clermont-Ferrand###Author: Xavier Moisset – Université Clermont Auvergne, CHU de Clermont-Ferrand, Inserm, Neuro-Dol, Clermont-Ferrand
### @@@ Justine Benevent – PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway ### 1900337###Author###Researcher###PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway###Author: Justine Benevent – PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway
### @@@ Marie Beslay, PhD – Toulouse University Hospital, CERPOP-SPHERE Team, Inserm UMR 1295, Toulouse University, France. ### 1900336###Author###Postdoctoral researcher###Toulouse University Hospital, CERPOP-SPHERE Team, Inserm UMR 1295, Toulouse University, France.###Author: Marie Beslay, PhD – Toulouse University Hospital, CERPOP-SPHERE Team, Inserm UMR 1295, Toulouse University, France.
### @@@ Claudia C. Bartolini – ARS Toscana ### 1063227###Author###Researcher###ARS Toscana###Author: Claudia C. Bartolini – ARS Toscana
### @@@ Marie-Agnès Bernard – Bordeaux PharmacoEpi, INSERM CIC-P1401, Univ. Bordeaux, 33000 Bordeaux, France ### 1658844###Author###Statistician###Bordeaux PharmacoEpi, INSERM CIC-P1401, Univ. Bordeaux, 33000 Bordeaux, France###Author: Marie-Agnès Bernard – Bordeaux PharmacoEpi, INSERM CIC-P1401, Univ. Bordeaux, 33000 Bordeaux, France
### @@@ Rosa Gini, PhD (she/her/hers) – ARS Toscana, Florence, Italy ### 1302758###Author###Head of Unit at ARS Toscana, Florence, Italy###ARS Toscana, Florence, Italy###Author: Rosa Gini, PhD (she/her/hers) – ARS Toscana, Florence, Italy
### she/her/hers @@@ Mika Gissler, PhD – Department of Knowledge Brokers, Finnish Institute for Health and Welfare, Helsinki ### 1360036###Author###Professor###Department of Knowledge Brokers, Finnish Institute for Health and Welfare, Helsinki###Author: Mika Gissler, PhD – Department of Knowledge Brokers, Finnish Institute for Health and Welfare, Helsinki
### @@@ Sue Jordan, MB.BCh., PhD. PGCE (FE), – Faculty of Medicine, Health and Life Sciences, Swansea University, Swansea ### 1359730###Author###professor###Faculty of Medicine, Health and Life Sciences, Swansea University, Swansea###Author: Sue Jordan, MB.BCh., PhD. PGCE (FE), – Faculty of Medicine, Health and Life Sciences, Swansea University, Swansea
### @@@ Régis Lassalle, MSc – Bordeaux PharmacoEpi, INSERM CIC-P1401, Univ. Bordeaux, 33000 Bordeaux, France ### 1358268###Author###Head of Statistics and Data management###Bordeaux PharmacoEpi, INSERM CIC-P1401, Univ. Bordeaux, 33000 Bordeaux, France###Author: Régis Lassalle, MSc – Bordeaux PharmacoEpi, INSERM CIC-P1401, Univ. Bordeaux, 33000 Bordeaux, France
### @@@ Maarit K. Leinonen, MD, PhD – Data and Analytics, Knowledge Brokers, Finnish Institute for Health and Welfare, Helsinki, Finland ### 1358190###Author###Associate professor###Data and Analytics, Knowledge Brokers, Finnish Institute for Health and Welfare, Helsinki, Finland###Author: Maarit K. Leinonen, MD, PhD – Data and Analytics, Knowledge Brokers, Finnish Institute for Health and Welfare, Helsinki, Finland
### @@@ Angela Lupattelli, MSc – Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway ### 1063068###Author###Associate Professor###Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway###Author: Angela Lupattelli, MSc – Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway
### @@@ Marco Manfrini – Department of Medical Sciences, Centre for Clinical and Epidemiological Research, Ferrara University, Italy ### 1900338###Author###Specialist in health statistics and biometrics###Department of Medical Sciences, Centre for Clinical and Epidemiological Research, Ferrara University, Italy###Author: Marco Manfrini – Department of Medical Sciences, Centre for Clinical and Epidemiological Research, Ferrara University, Italy
### @@@ Visa Martikainen – Department of Knowledge Brokers, Finnish Institute for Health and Welfare, Helsinki, Finland ### 1359729###Author###Data manager, statistician###Department of Knowledge Brokers, Finnish Institute for Health and Welfare, Helsinki, Finland###Author: Visa Martikainen – Department of Knowledge Brokers, Finnish Institute for Health and Welfare, Helsinki, Finland
### @@@ Joan K. Morris – St George's, University of London, London ### 1900343###Author###Professor###St George's, University of London, London###Author: Joan K. Morris – St George's, University of London, London
### @@@ Amanda j. Neville, N/A – Registro IMER University of Ferrara and Azienda Ospedaliero Universitario S Anna, Ferrara, Italy ### 1359720###Author###Registry Leader, IMER Registry###Registro IMER University of Ferrara and Azienda Ospedaliero Universitario S Anna, Ferrara, Italy###Author: Amanda j. Neville, N/A – Registro IMER University of Ferrara and Azienda Ospedaliero Universitario S Anna, Ferrara, Italy
### @@@ Hedvig Nordeng, PhD – Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway ### 1358057###Author###Professor###Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway###Author: Hedvig Nordeng, PhD – Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway
### @@@ Olga Paoletti – Regional Health Agency of Tuscany, Pharmacoepidemiology Unit, Florence, Italy ### 1359270###Author###Researcher###Regional Health Agency of Tuscany, Pharmacoepidemiology Unit, Florence, Italy###Author: Olga Paoletti – Regional Health Agency of Tuscany, Pharmacoepidemiology Unit, Florence, Italy
### @@@ Jingping Mo – Worldwide Medical and Safety, Pfizer Inc., New York, NY ### 1358153###Author###Professor###Worldwide Medical and Safety, Pfizer Inc., New York, NY###Author: Jingping Mo – Worldwide Medical and Safety, Pfizer Inc., New York, NY
### @@@ Christine Damase-Michel, PhD, PharmD – Université Toulouse III ### 1358255###Author###Associate Professor in Pharmacology###Université Toulouse III###Author: Christine Damase-Michel, PhD, PharmD – Université Toulouse III
### OP1-4Presenting Author: Núria Mercadé Besora (she/her/hers) – IDIAP Jordi Gol
### she/her/hers @@@ Daniel Prieto-Alhambra, MD MSc(Oxon) PhD (he/him/his) – University of Oxford, Erasmus MC University ### 1062615###Author###Professor of Pharmaco- and Device Epidemiology, Professor of RWE###University of Oxford, Erasmus MC University###Author: Daniel Prieto-Alhambra, MD MSc(Oxon) PhD (he/him/his) – University of Oxford, Erasmus MC University
### he/him/his @@@ Elena Roel, MD – Fundació Institut Universitari per a la recerca a l’Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol) ### 1360486###Author###PhD student###Fundació Institut Universitari per a la recerca a l’Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol)###Author: Elena Roel, MD – Fundació Institut Universitari per a la recerca a l’Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol)
### @@@ Antonella Delmestri, PhD (she/her/hers) – Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford ### 1358614###Author###Lead Health Data Scientist###Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford###Author: Antonella Delmestri, PhD (she/her/hers) – Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford
### she/her/hers @@@ Clara Prats, PHD (she/her/hers) – Universitat Politècnica de Catalunya ### 1358939###Author###Professor and Researcher###Universitat Politècnica de Catalunya###Author: Clara Prats, PHD (she/her/hers) – Universitat Politècnica de Catalunya
### she/her/hers @@@ Annika M. Jödicke, PhD (she/her/hers) – University of Oxford ### 1358980###Author###Senior Researcher in Pharmacoepidemiology###University of Oxford###Author: Annika M. Jödicke, PhD (she/her/hers) – University of Oxford
### she/her/hers @@@ Martí Català Sabaté, PhD (he/him/his) – Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford ### 1659148###Author###Senior Data Scientist###Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford###Author: Martí Català Sabaté, PhD (he/him/his) – Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford
### he/him/his OP4-5Author: Xiaomo Xiong, MS – College of Pharmacy, University of South Carolina
### @@@ Sam Li, PhD – University of Tennessee Health Science Center ### 1359863###Author###Assistant Professor###University of Tennessee Health Science Center###Author: Sam Li, PhD – University of Tennessee Health Science Center
### @@@ Xiaoxia Wang – University of South Carolina ### 1659234###Author###PharmD Student###University of South Carolina###Author: Xiaoxia Wang – University of South Carolina
### @@@ Gang Lv, MD – Chinese PLA General Hospital ### 1659238###Author###Deputy Chief Physician###Chinese PLA General Hospital###Author: Gang Lv, MD – Chinese PLA General Hospital
### @@@ Kevin Lu, PhD, FISPE – University of South Carolina ### 1093581###Presenting Author###Associate Professor###University of South Carolina###Presenting Author: Kevin Lu, PhD, FISPE – University of South Carolina
### OP2-4Presenting Author: Basavaraj Ramappa Poojar, Msc Medical Pharmacology, Final year PhD (he/him/his) – Kasturba Medical College, Light House Hill Road, Mangalore
### he/him/his @@@ Ashok Shenoy K (he/him/his) – Kasturba Medical College, Light House Hill Road, Mangalore ### 1900313###Author###Professor,###Kasturba Medical College, Light House Hill Road, Mangalore###Author: Ashok Shenoy K (he/him/his) – Kasturba Medical College, Light House Hill Road, Mangalore
### he/him/his @@@ Ashwin Kamath, MD (he/him/his) – Kasturba Medical College, Mangalore, Manipal Academy of Higher Education, Manipal ### 1062820###Author###Associate Professor,###Kasturba Medical College, Mangalore, Manipal Academy of Higher Education, Manipal###Author: Ashwin Kamath, MD (he/him/his) – Kasturba Medical College, Mangalore, Manipal Academy of Higher Education, Manipal
### he/him/his @@@ John Ramapuram (he/him/his) – Kasturba Medical College, Light House Hill Road, Mangalore ### 1900314###Author###Professor,###Kasturba Medical College, Light House Hill Road, Mangalore###Author: John Ramapuram (he/him/his) – Kasturba Medical College, Light House Hill Road, Mangalore
### he/him/his @@@ Sathish B Rao (he/him/his) – Kasturba Medical College, Light House Hill Road, Mangalore ### 1900315###Author###Professor,###Kasturba Medical College, Light House Hill Road, Mangalore###Author: Sathish B Rao (he/him/his) – Kasturba Medical College, Light House Hill Road, Mangalore
### he/him/his OP3-5Presenting Author: Christine C. van Hattem, MSc – Utrecht University
### @@@ Amos de Jong, Msc – Utrecht University ### 1657663###Author###PhD student###Utrecht University###Author: Amos de Jong, Msc – Utrecht University
### @@@ Jolien S. de Groot, MD, PhD – Dutch Medicines Evaluation Board ### 1900383###Author###Clinical Assessor###Dutch Medicines Evaluation Board###Author: Jolien S. de Groot, MD, PhD – Dutch Medicines Evaluation Board
### @@@ Lourens T. Bloem, PharmD, PhD (he/him/his) – Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University ### 1063247###Author###Assistant Professor Clinical Therapeutics###Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University###Author: Lourens T. Bloem, PharmD, PhD (he/him/his) – Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University
### he/him/his OP4-1Presenting Author: Qi Zhang, MSPH (she/her/hers) – Department of Epidemiology, Emory University
### she/her/hers @@@ Michael Goodman, MD, MPH (he/him/his) – Emory University ### 1900258###Author###Professor###Emory University###Author: Michael Goodman, MD, MPH (he/him/his) – Emory University
### he/him/his OP1-1Presenting Author: Courtney A. Johnson, MPH (she/her/hers) – Brown University
### she/her/hers @@@ Theresa I. Shireman, PhD (she/her/hers) – Brown University ### 1658623###Author###Director Center for Gerontology & Health Care Research, Professor Health Services, Policy, &Practice###Brown University###Author: Theresa I. Shireman, PhD (she/her/hers) – Brown University
### she/her/hers @@@ Amal N. Trivedi, MD, MPH – Brown University ### 1900323###Author###Professor of Health Services, Policy & Practice, Professor of Medicine###Brown University###Author: Amal N. Trivedi, MD, MPH – Brown University
### @@@ Omar Galárraga, PhD (he/him/his) – Brown University ### 1900324###Author###Director of PhD Program in Health Services, Policy & Practice (HSPP), Associate Professor of HSPP###Brown University###Author: Omar Galárraga, PhD (he/him/his) – Brown University
### he/him/his OP2-2Presenting Author: Grace (Hsin Min) Wang (she/her/hers) – University of Florida College of Pharmacy
### she/her/hers @@@ Scott Vouri (he/him/his) – Real World Evidence Internal Medicine, Pfizer ### 1900262###Author###Director###Real World Evidence Internal Medicine, Pfizer###Author: Scott Vouri (he/him/his) – Real World Evidence Internal Medicine, Pfizer
### he/him/his @@@ Steven Smith (he/him/his) – Department of Pharmaceutical Outcomes and Policy, University of Florida College of Pharmacy, Gainesville, FL, USA ### 1900261###Author###Assistant professor###Department of Pharmaceutical Outcomes and Policy, University of Florida College of Pharmacy, Gainesville, FL, USA###Author: Steven Smith (he/him/his) – Department of Pharmaceutical Outcomes and Policy, University of Florida College of Pharmacy, Gainesville, FL, USA
### he/him/his @@@ Wei-Hsuan Lo-Ciganic (she/her/hers) – Department of Pharmaceutical Outcomes & Policy, University of Florida College of Pharmacy ### 1900260###Author###Associate Professor###Department of Pharmaceutical Outcomes & Policy, University of Florida College of Pharmacy###Author: Wei-Hsuan Lo-Ciganic (she/her/hers) – Department of Pharmaceutical Outcomes & Policy, University of Florida College of Pharmacy
### she/her/hers OP2-5Presenting Author: Þorsteinn Ívar Albertsson, BSc (he/him/his) – Faculty of Medicine, University of Iceland, Reykjavík, Iceland
### he/him/his @@@ Freyja Jonsdottir, MSc (she/her/hers) – Faculty of Pharmaceutical Sciences, University of Iceland, Reykjavík, Iceland; Hospital Pharmacy Landspítali–The National University Hospital, Reykjavík, Iceland ### 1900348###Author###Assistant Professor, University of Iceland; Clinical Pharmacist, Landspitali University Hospita.###Faculty of Pharmaceutical Sciences, University of Iceland, Reykjavík, Iceland; Hospital Pharmacy Landspítali–The National University Hospital, Reykjavík, Iceland###Author: Freyja Jonsdottir, MSc (she/her/hers) – Faculty of Pharmaceutical Sciences, University of Iceland, Reykjavík, Iceland; Hospital Pharmacy Landspítali–The National University Hospital, Reykjavík, Iceland
### she/her/hers @@@ Sigurbergur Kárason, MD, PhD, EMPH – Faculty of Medicine, University of Iceland, Reykjavík, Iceland; Department of Anesthesiology and Critical Care Medicine, Landspitali–The National University Hospital, Reykjavík, Iceland. ### 1900385###Author###Professor, University of Iceland; Head of Anaesthesia, Landspitali University Hospital.###Faculty of Medicine, University of Iceland, Reykjavík, Iceland; Department of Anesthesiology and Critical Care Medicine, Landspitali–The National University Hospital, Reykjavík, Iceland.###Author: Sigurbergur Kárason, MD, PhD, EMPH – Faculty of Medicine, University of Iceland, Reykjavík, Iceland; Department of Anesthesiology and Critical Care Medicine, Landspitali–The National University Hospital, Reykjavík, Iceland.
### @@@ Martin Ingi I. Sigurdsson, MD, PhD (he/him/his) – Faculty of Medicine, University of Iceland, Reykjavík, Iceland; Department of Anesthesiology and Critical Care Medicine, Landspitali–The National University Hospital, Reykjavík, Iceland. ### 1900347###Author###Professor, University of Iceland; Chief Physician, Landspitali University Hospital.###Faculty of Medicine, University of Iceland, Reykjavík, Iceland; Department of Anesthesiology and Critical Care Medicine, Landspitali–The National University Hospital, Reykjavík, Iceland.###Author: Martin Ingi I. Sigurdsson, MD, PhD (he/him/his) – Faculty of Medicine, University of Iceland, Reykjavík, Iceland; Department of Anesthesiology and Critical Care Medicine, Landspitali–The National University Hospital, Reykjavík, Iceland.
### he/him/his OP3-3Presenting Author: Victoria A. Fuchs – 1.Clinical Pharmacy Research Group, Louvain Drug Research Institute (LDRI), Université catholique de Louvain, Brussels, Belgium ; 2.Institute of Health and Society (IRSS), Université catholique de Louvain, Brussels, Belgium
### @@@ Anne Spinewine – 1.Clinical Pharmacy Research Group, Louvain Drug Research Institute (LDRI), Université catholique de Louvain, Brussels, Belgium ; 2.Pharmacy Department, CHU UCL Namur, Belgium ### 1900256###Author###Full professor###1.Clinical Pharmacy Research Group, Louvain Drug Research Institute (LDRI), Université catholique de Louvain, Brussels, Belgium ; 2.Pharmacy Department, CHU UCL Namur, Belgium###Author: Anne Spinewine – 1.Clinical Pharmacy Research Group, Louvain Drug Research Institute (LDRI), Université catholique de Louvain, Brussels, Belgium ; 2.Pharmacy Department, CHU UCL Namur, Belgium
### @@@ Séverine Henrard – 1. Clinical Pharmacy Research Group, Louvain Drug Research Institute (LDRI), Université catholique de Louvain, Brussels, Belgium. 2. Institute of Health and Society (IRSS), Université catholique de Louvain, Brussels, Belgium ### 1900257###Author###Associate professor###1. Clinical Pharmacy Research Group, Louvain Drug Research Institute (LDRI), Université catholique de Louvain, Brussels, Belgium. 2. Institute of Health and Society (IRSS), Université catholique de Louvain, Brussels, Belgium###Author: Séverine Henrard – 1. Clinical Pharmacy Research Group, Louvain Drug Research Institute (LDRI), Université catholique de Louvain, Brussels, Belgium. 2. Institute of Health and Society (IRSS), Université catholique de Louvain, Brussels, Belgium
### OP2-1Moderator: Larus S. Gudmundsson (he/him/his) – University of Iceland
### he/him/his @@@ Almut G. Winterstein, PhD, FISPE – University of Florida, Pharmaceutical Outcomes & Policy, Center for Drug Evaluation & Safety ### 1061393###Moderator###Distinguished Professor###University of Florida, Pharmaceutical Outcomes & Policy, Center for Drug Evaluation & Safety###Moderator: Almut G. Winterstein, PhD, FISPE – University of Florida, Pharmaceutical Outcomes & Policy, Center for Drug Evaluation & Safety
### @@@ Martin Ingi I. Sigurdsson, MD, PhD (he/him/his) – Faculty of Medicine, University of Iceland, Reykjavík, Iceland; Department of Anesthesiology and Critical Care Medicine, Landspitali–The National University Hospital, Reykjavík, Iceland. ### 1900347###Speaker###Professor, University of Iceland; Chief Physician, Landspitali University Hospital.###Faculty of Medicine, University of Iceland, Reykjavík, Iceland; Department of Anesthesiology and Critical Care Medicine, Landspitali–The National University Hospital, Reykjavík, Iceland.###Speaker: Martin Ingi I. Sigurdsson, MD, PhD (he/him/his) – Faculty of Medicine, University of Iceland, Reykjavík, Iceland; Department of Anesthesiology and Critical Care Medicine, Landspitali–The National University Hospital, Reykjavík, Iceland.
### he/him/his @@@ Guðrún Aspelund (she/her/hers) – Directorate of Health Iceland ### 1901666###Speaker###Chief Epidemiologist###Directorate of Health Iceland###Speaker: Guðrún Aspelund (she/her/hers) – Directorate of Health Iceland
### she/her/hers @@@ Menno van der Elst (he/him/his) – Dutch Medicines Evaluation Board ### 1901668###Speaker###Member###Dutch Medicines Evaluation Board###Speaker: Menno van der Elst (he/him/his) – Dutch Medicines Evaluation Board
### he/him/hisModerator: Helga Gardarsdottir, PharmD, PhD, FISPE (she/her/hers) – Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, The Netherlands
### she/her/hers @@@ Tobias Gerhard, PhD (he/him/his) – Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research ### 1046831###Moderator###Professor and Director###Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research###Moderator: Tobias Gerhard, PhD (he/him/his) – Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research
### he/him/his @@@ Anne M. Butler, PhD, MS – Washington University School of Medicine ### 1062638###Speaker###Assistant Professor###Washington University School of Medicine###Speaker: Anne M. Butler, PhD, MS – Washington University School of Medicine
### @@@ Michael Andrew Webster-Clark, PharmD, PhD (he/him/his) – McGill University ### 1062566###Speaker###Assistant Professor###McGill University###Speaker: Michael Andrew Webster-Clark, PharmD, PhD (he/him/his) – McGill University
### he/him/his @@@ Morten Andersen, MD, PhD – Pharmacovigilance Research Center, Department of Drug Design and Pharmacology, University of Copenhagen ### 1302750###Speaker###Professor###Pharmacovigilance Research Center, Department of Drug Design and Pharmacology, University of Copenhagen###Speaker: Morten Andersen, MD, PhD – Pharmacovigilance Research Center, Department of Drug Design and Pharmacology, University of Copenhagen
###Moderator: Maurizio Sessa, PharmD – University of Copenhagen
### @@@ Vincent Lo Re, III, MD, MSCE (he/him/his) – Perelman School of Medicine at the University of Pennsylvania ### 1359970###Moderator###Associate Professor of Medicine and Epidemiology###Perelman School of Medicine at the University of Pennsylvania###Moderator: Vincent Lo Re, III, MD, MSCE (he/him/his) – Perelman School of Medicine at the University of Pennsylvania
### he/him/his @@@ Andrew Bate – GlaxoSmithKline ### 1088314###Speaker###VP & Head, Safety Innovation & Analytics, Global Safety###GlaxoSmithKline###Speaker: Andrew Bate – GlaxoSmithKline
### @@@ Larus S. Gudmundsson (he/him/his) – University of Iceland ### 1901667###Speaker###Associate Professor###University of Iceland###Speaker: Larus S. Gudmundsson (he/him/his) – University of Iceland
### he/him/his @@@ David O. Arnar – University of Iceland ### 1901688###Speaker###Professoe###University of Iceland###Speaker: David O. Arnar – University of Iceland
###Moderator: Andrew Bate – GlaxoSmithKline
### @@@ Susana Perez-Gutthann, MD, MPH, PhD, FISPE, FRCP – Research Triangle Institute ### 1061396###Moderator###VP Epidemiology###Research Triangle Institute###Moderator: Susana Perez-Gutthann, MD, MPH, PhD, FISPE, FRCP – Research Triangle Institute
### @@@ Alison Cave, PhD – Medicines and Healthcare products Regulatory Agency (UK) ### 1901771###Speaker###Chief Safety Officer###Medicines and Healthcare products Regulatory Agency (UK)###Speaker: Alison Cave, PhD – Medicines and Healthcare products Regulatory Agency (UK)
### @@@ Robert W. Platt, PhD (he/him/his) – Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada ### 1358167###Speaker###Professor###Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada###Speaker: Robert W. Platt, PhD (he/him/his) – Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada
### he/him/his @@@ Jamie Geier (she/her/hers) – Novartis Pharma AG ### 1359033###Speaker###Global Head, Quantitative Safety & Epidemiology###Novartis Pharma AG###Speaker: Jamie Geier (she/her/hers) – Novartis Pharma AG
### she/her/hersPresenting Author: Meghan Cupp Buxton, BSc, MPH (she/her/hers) – Department of Epidemiology, Brown University School of Public Health
### she/her/hers @@@ Francesca L. Beaudoin, MD, PhD – Department of Epidemiology, Brown University School of Public Health ### 1358486###Author###Associate Professor###Department of Epidemiology, Brown University School of Public Health###Author: Francesca L. Beaudoin, MD, PhD – Department of Epidemiology, Brown University School of Public Health
### @@@ Kaleen N. Hayes, PharmD, PhD (she/her/hers) – Brown University School of Public Health, Providence, Rhode Island, USA ### 1062830###Author###Assistant Professor###Brown University School of Public Health, Providence, Rhode Island, USA###Author: Kaleen N. Hayes, PharmD, PhD (she/her/hers) – Brown University School of Public Health, Providence, Rhode Island, USA
### she/her/hers @@@ Melissa R. Riester, PharmD – Brown University School of Public Health ### 1302727###Author###Research Scientist###Brown University School of Public Health###Author: Melissa R. Riester, PharmD – Brown University School of Public Health
### @@@ Sarah Berry, MD, MPH – Department of Medicine, Beth Israel Deaconess Medical Center ### 1659409###Author###Associate Professor of Medicine###Department of Medicine, Beth Israel Deaconess Medical Center###Author: Sarah Berry, MD, MPH – Department of Medicine, Beth Israel Deaconess Medical Center
### @@@ Richa Joshi, MS, MBA – Department of Health Services, Policy, and Practice, Brown University School of Public Health ### 1655733###Author###Data Science Analyst###Department of Health Services, Policy, and Practice, Brown University School of Public Health###Author: Richa Joshi, MS, MBA – Department of Health Services, Policy, and Practice, Brown University School of Public Health
### @@@ Andrew R. Zullo, PharmD, PhD (he/him/his) – Brown University School of Public Health ### 1302736###Author###Associate Professor###Brown University School of Public Health###Author: Andrew R. Zullo, PharmD, PhD (he/him/his) – Brown University School of Public Health
### he/him/his OP3-6Presenting Author: Oliver W. Scott, BHSc (first class hons) – University of Auckland
### @@@ Sandar TinTin, PhD – University of Auckland ### 1358076###Author###Senior Research Fellow###University of Auckland###Author: Sandar TinTin, PhD – University of Auckland
### @@@ Sixten Harborg, PhD/MD student – Aarhus University ### 1900223###Author###PhD student###Aarhus University###Author: Sixten Harborg, PhD/MD student – Aarhus University
### @@@ Marion Kuper-Hommel, MD, FRACP, PhD – Waikato District Health Board ### 1900224###Author###Oncologist###Waikato District Health Board###Author: Marion Kuper-Hommel, MD, FRACP, PhD – Waikato District Health Board
### @@@ Ross Lawrenson, MD – University of Waikato ### 1900225###Author###Professor in Population Health###University of Waikato###Author: Ross Lawrenson, MD – University of Waikato
### @@@ Mark Elwood, MD – University of Auckland ### 1358078###Author###Professor of Cancer Epidemiology###University of Auckland###Author: Mark Elwood, MD – University of Auckland
### OP2-6Presenting Author: Steve Ferreira Guerra – McGill University
### @@@ Robert W. Platt, PhD (he/him/his) – Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada ### 1358167###Author###Professor###Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada###Author: Robert W. Platt, PhD (he/him/his) – Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada
### he/him/his @@@ Michal Abrahamowicz, PhD – McGill University ### 1358206###Author###Professor###McGill University###Author: Michal Abrahamowicz, PhD – McGill University
### OP4-4Presenting Author: Claudia Bruno, BSc(hon) (she/her/hers) – School of Population Health, University of New South Wales; Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway
### she/her/hers @@@ Carolyn E. Cesta, PhD – Centre for Pharmacoepidemiology, Karolinska Institutet ### 1062759###Author###Researcher###Centre for Pharmacoepidemiology, Karolinska Institutet###Author: Carolyn E. Cesta, PhD – Centre for Pharmacoepidemiology, Karolinska Institutet
### @@@ Vidar Hjellvik, PhD – Norwegian Institute of Public Health ### 1358617###Author###Statistician###Norwegian Institute of Public Health###Author: Vidar Hjellvik, PhD – Norwegian Institute of Public Health
### @@@ Sinna Pilgaard Ulrichsen, MSc (she/her/hers) – Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University and Aarhus University Hospital, Aarhus, Denmark ### 1360037###Author###Biostatistician###Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University and Aarhus University Hospital, Aarhus, Denmark###Author: Sinna Pilgaard Ulrichsen, MSc (she/her/hers) – Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University and Aarhus University Hospital, Aarhus, Denmark
### she/her/hers @@@ Marte-Helene h. Bjørk, MD, PhD – NorHEAD Norwegian Centre for Headache Research, Department of Clinical Medicine, University of Bergen, Bergen, Norway Jonas Lies vei 87 5021, Bergen Norway ### 1360035###Author###Professor, consultant neurologist###NorHEAD Norwegian Centre for Headache Research, Department of Clinical Medicine, University of Bergen, Bergen, Norway Jonas Lies vei 87 5021, Bergen Norway###Author: Marte-Helene h. Bjørk, MD, PhD – NorHEAD Norwegian Centre for Headache Research, Department of Clinical Medicine, University of Bergen, Bergen, Norway Jonas Lies vei 87 5021, Bergen Norway
### @@@ Buket Öztürk Esen, MSc – Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University and Aarhus University Hospital, Aarhus, Denmark ### 1062595###Author###PhD candidate###Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University and Aarhus University Hospital, Aarhus, Denmark###Author: Buket Öztürk Esen, MSc – Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University and Aarhus University Hospital, Aarhus, Denmark
### @@@ Malcolm B. Gillies, PhD (he/him/his) – School of Population Health, University of New South Wales ### 1359563###Author###Senior Biostatistician###School of Population Health, University of New South Wales###Author: Malcolm B. Gillies, PhD (he/him/his) – School of Population Health, University of New South Wales
### he/him/his @@@ Mika Gissler, PhD – Department of Knowledge Brokers, Finnish Institute for Health and Welfare, Helsinki ### 1360036###Author###Professor###Department of Knowledge Brokers, Finnish Institute for Health and Welfare, Helsinki###Author: Mika Gissler, PhD – Department of Knowledge Brokers, Finnish Institute for Health and Welfare, Helsinki
### @@@ Alys Havard, PhD (she/her/hers) – National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia ### 1358233###Author###Senior Research Fellow###National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia###Author: Alys Havard, PhD (she/her/hers) – National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia
### she/her/hers @@@ Pär Karlsson, MSc (he/him/his) – Centre for Pharmacoepidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden ### 1360225###Author###Statistician###Centre for Pharmacoepidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden###Author: Pär Karlsson, MSc (he/him/his) – Centre for Pharmacoepidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden
### he/him/his @@@ Øystein Karlstad, MscPharm, PhD – Department of Chronic Diseases, Norwegian Institute of Public Health ### 1358431###Author###Senior researcher###Department of Chronic Diseases, Norwegian Institute of Public Health###Author: Øystein Karlstad, MscPharm, PhD – Department of Chronic Diseases, Norwegian Institute of Public Health
### @@@ Maarit K. Leinonen, MD, PhD – Data and Analytics, Knowledge Brokers, Finnish Institute for Health and Welfare, Helsinki, Finland ### 1358190###Author###Associate professor###Data and Analytics, Knowledge Brokers, Finnish Institute for Health and Welfare, Helsinki, Finland###Author: Maarit K. Leinonen, MD, PhD – Data and Analytics, Knowledge Brokers, Finnish Institute for Health and Welfare, Helsinki, Finland
### @@@ Mette Nørgaard, MD, PhD – Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University and Aarhus University Hospital, Aarhus, Denmark ### 1063034###Author###Chief physician, professor###Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University and Aarhus University Hospital, Aarhus, Denmark###Author: Mette Nørgaard, MD, PhD – Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University and Aarhus University Hospital, Aarhus, Denmark
### @@@ Sallie-Anne Pearson, PhD – School of Population Health, Faculty of Medicine and Health, University of New South Wales, Sydney, Australia ### 1358403###Author###Professor###School of Population Health, Faculty of Medicine and Health, University of New South Wales, Sydney, Australia###Author: Sallie-Anne Pearson, PhD – School of Population Health, Faculty of Medicine and Health, University of New South Wales, Sydney, Australia
### @@@ Johan Reutfors, MD, PhD – Centre for Pharmacoepidemiology, Karolinska Institutet ### 1358377###Author###Associate professor###Centre for Pharmacoepidemiology, Karolinska Institutet###Author: Johan Reutfors, MD, PhD – Centre for Pharmacoepidemiology, Karolinska Institutet
### @@@ Hein Stigum, PhD – Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway ### 1659382###Author###Statistician###Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway###Author: Hein Stigum, PhD – Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway
### @@@ Kari Furu, PhD – Department of Chronic Diseases & Centre for Fertility and Health, Norwegian Institute of Public Health ### 1063219###Author###Senior researcher###Department of Chronic Diseases & Centre for Fertility and Health, Norwegian Institute of Public Health###Author: Kari Furu, PhD – Department of Chronic Diseases & Centre for Fertility and Health, Norwegian Institute of Public Health
### @@@ Jacqueline Cohen, PhD (she/her/hers) – Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway ### 1900239###Author###Senior researcher###Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway###Author: Jacqueline Cohen, PhD (she/her/hers) – Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway
### she/her/hers @@@ Helga Zoega – University of New South Wales - Sydney ### 1358124###Author###Associate professor/professor###University of New South Wales - Sydney###Author: Helga Zoega – University of New South Wales - Sydney
### OP1-6Presenting Author: Milica Zugic, MScPharm – Department of Pharmacy, University of Oslo, Oslo, Norway
### @@@ Nhung Trinh, PhD – PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Research Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo ### 1655801###Author###Postdoctoral Fellow###PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Research Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo###Author: Nhung Trinh, PhD – PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Research Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo
### @@@ Hedvig Nordeng, PhD – Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway ### 1358057###Author###Professor###Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway###Author: Hedvig Nordeng, PhD – Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway
### @@@ Angela Lupattelli, MSc – Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway ### 1063068###Author###Associate Professor###Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway###Author: Angela Lupattelli, MSc – Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, and PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway
### OP1-5Speaker: Tobias Gerhard, PhD, FISPE (he/him/his) – Center for Pharmacoepidemiology and Treatment Science, Rutgers University
### he/him/his @@@ Almut G. Winterstein, PhD, FISPE – University of Florida, Pharmaceutical Outcomes & Policy, Center for Drug Evaluation & Safety ### 1061393###Speaker###Distinguished Professor###University of Florida, Pharmaceutical Outcomes & Policy, Center for Drug Evaluation & Safety###Speaker: Almut G. Winterstein, PhD, FISPE – University of Florida, Pharmaceutical Outcomes & Policy, Center for Drug Evaluation & Safety
### @@@ Tania Schink, Dr, MPH (she/her/hers) – Leibniz Institute for Prevention Research and Epidemiology - BIPS ### 1062583###Speaker###Senior scientist###Leibniz Institute for Prevention Research and Epidemiology - BIPS###Speaker: Tania Schink, Dr, MPH (she/her/hers) – Leibniz Institute for Prevention Research and Epidemiology - BIPS
### she/her/hersPresenting Author: Renske Grupstra (she/her/hers) – Utrecht University
### she/her/hers @@@ Thomas Goedecke, Dr. – European Medicines Agency ### 1659475###Author###Senior Pharmacovigilance Specialist###European Medicines Agency###Author: Thomas Goedecke, Dr. – European Medicines Agency
### @@@ Helga Gardarsdottir, PharmD, PhD, – Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht University ### 1061395###Author###Associate professor###Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht University###Author: Helga Gardarsdottir, PharmD, PhD, – Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht University
### OP4-2Moderator: Lisa G. Pont, PhD – Discipline of Pharmacy, University of Technology Sydney, Sydney, NSW, Australia
### @@@ Sebastian Jugl, BPharm, RPh (he/him/his) – University of Florida ### 1063291###Moderator###PhD Student###University of Florida###Moderator: Sebastian Jugl, BPharm, RPh (he/him/his) – University of Florida
### he/him/his OP1-0Moderator: Marie Louise L. De Bruin, PhD (she/her/hers) – Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University
### she/her/hers @@@ Michael Andrew Webster-Clark, PharmD, PhD (he/him/his) – McGill University ### 1062566###Moderator###Assistant Professor###McGill University###Moderator: Michael Andrew Webster-Clark, PharmD, PhD (he/him/his) – McGill University
### he/him/his OP2-0Moderator: Freyja Jonsdottir, MSc (she/her/hers) – Faculty of Pharmaceutical Sciences, University of Iceland, Reykjavík, Iceland; Hospital Pharmacy Landspítali–The National University Hospital, Reykjavík, Iceland
### she/her/hers @@@ Jessica C. Young, PhD (she/her/hers) – Karolinska Institutet ### 1932107###Moderator###Postdoctoral Researcher###Karolinska Institutet###Moderator: Jessica C. Young, PhD (she/her/hers) – Karolinska Institutet
### she/her/hers OP3-0Moderator: Deborah Layton, PhD, FISPE – PEPI Consultancy Limited
### @@@ Claudia Bruno, BSc(hon) (she/her/hers) – School of Population Health, University of New South Wales; Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway ### 1062978###Moderator###PhD candidate###School of Population Health, University of New South Wales; Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway###Moderator: Claudia Bruno, BSc(hon) (she/her/hers) – School of Population Health, University of New South Wales; Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway
### she/her/hers OP4-0Presenting Author: Jeff Y. Yang, MSPH (he/him/his) – GSK
### he/him/his @@@ Jennifer L. Lund, PhD, FISPE (she/her/hers) – Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill ### 1062592###Author###Associate Professor###Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill###Author: Jennifer L. Lund, PhD, FISPE (she/her/hers) – Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill
### she/her/hers @@@ Michele Jonsson Funk, PhD, FISPE (she/her/hers) – UNC Chapel Hill Gillings School of Global Public Health ### 1046824###Author###Associate Professor###UNC Chapel Hill Gillings School of Global Public Health###Author: Michele Jonsson Funk, PhD, FISPE (she/her/hers) – UNC Chapel Hill Gillings School of Global Public Health
### she/her/hers @@@ Michael Hudgens, PhD – Gillings School of Global Public Health, University of North Carolina at Chapel Hill ### 1358428###Author###Professor and Associate Chair###Gillings School of Global Public Health, University of North Carolina at Chapel Hill###Author: Michael Hudgens, PhD – Gillings School of Global Public Health, University of North Carolina at Chapel Hill
### @@@ James D. Lewis, MD MSCE – Division of Gastroenterology and Hepatology, Perelman School of Medicine at the University of Pennsylvania ### 1900328###Author###Professor of Medicine and Epidemiology###Division of Gastroenterology and Hepatology, Perelman School of Medicine at the University of Pennsylvania###Author: James D. Lewis, MD MSCE – Division of Gastroenterology and Hepatology, Perelman School of Medicine at the University of Pennsylvania
### @@@ Michael D. Kappelman, MD, MPH – Division of Pediatric Gastroenterology, Department of Pediatrics, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC ### 1359502###Author###Professor###Division of Pediatric Gastroenterology, Department of Pediatrics, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC###Author: Michael D. Kappelman, MD, MPH – Division of Pediatric Gastroenterology, Department of Pediatrics, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC
### OP3-4